scholarly journals Activation of Peroxisome Proliferator-activated Receptor α (PPARα) Suppresses Hypoxia-inducible Factor-1α (HIF-1α) Signaling in Cancer Cells

2012 ◽  
Vol 287 (42) ◽  
pp. 35161-35169 ◽  
Author(s):  
Jundong Zhou ◽  
Shuyu Zhang ◽  
Jing Xue ◽  
Jori Avery ◽  
Jinchang Wu ◽  
...  

Activation of peroxisome proliferator-activated receptor α (PPARα) has been demonstrated to inhibit tumor growth and angiogenesis, yet the mechanisms behind these actions remain to be characterized. In this study, we examined the effects of PPARα activation on the hypoxia-inducible factor-1α (HIF-1α) signaling pathway in human breast (MCF-7) and ovarian (A2780) cancer cells under hypoxia. Incubation of cancer cells under 1% oxygen for 16 h significantly induced HIF-1α expression and activity as assayed by Western blotting and reporter gene analysis. Treatment of the cells with PPARα agonists, but not a PPARγ agonist, prior to hypoxia diminished hypoxia-induced HIF-1α expression and activity, and addition of a PPARα antagonist attenuated the suppression of HIF-1α signaling. Activation of PPARα attenuated hypoxia-induced HA-tagged HIF-1α protein expression without affecting the HA-tagged HIF-1α mutant protein level, indicating that PPARα activation promotes HIF-1α degradation in these cells. This was further confirmed using proteasome inhibitors, which reversed PPARα-mediated suppression of HIF-1α expression under hypoxia. Using the co-immunoprecipitation technique, we found that activation of PPARα enhances the binding of HIF-1α to von Hippel-Lindau tumor suppressor (pVHL), a protein known to mediate HIF-1α degradation through the ubiquitin-proteasome pathway. Following PPARα-mediated suppression of HIF-1α signaling, VEGF secretion from the cancer cells was significantly reduced, and tube formation by endothelial cells was dramatically impaired. Taken together, these findings demonstrate for the first time that activation of PPARα suppresses hypoxia-induced HIF-1α signaling in cancer cells, providing novel insight into the anticancer properties of PPARα agonists.

2015 ◽  
Vol 468 (3) ◽  
pp. 409-423 ◽  
Author(s):  
Caryn S. Gonsalves ◽  
Chen Li ◽  
Marthe-Sandrine Eiymo Mwa Mpollo ◽  
Vinod Pullarkat ◽  
Punam Malik ◽  
...  

We showed that erythropoietin (EPO)-mediated activation of hypoxia-inducible factor-1α (HIF-1α) increased the expression of placental growth factor (PlGF). Furthermore, miR-214 post-transcriptionally regulates PlGF expression. miR-214 itself is regulated by both peroxisome proliferator-activated receptor-α (PPARα) and HIF-1α, thus providing a novel approach for reduction in PlGF levels in sickle cell disease (SCD).


2014 ◽  
Vol 289 (52) ◽  
pp. 36031-36047 ◽  
Author(s):  
Chen Li ◽  
Marthe-Sandrine Eiymo Mwa Mpollo ◽  
Caryn S. Gonsalves ◽  
Stanley M. Tahara ◽  
Punam Malik ◽  
...  

2006 ◽  
Vol 26 (20) ◽  
pp. 7561-7574 ◽  
Author(s):  
Jean-Sébastien Annicotte ◽  
Irena Iankova ◽  
Stéphanie Miard ◽  
Vanessa Fritz ◽  
David Sarruf ◽  
...  

ABSTRACT Peroxisome proliferator-activated receptor γ (PPARγ) might not be permissive to ligand activation in prostate cancer cells. Association of PPARγ with repressing factors or posttranslational modifications in PPARγ protein could explain the lack of effect of PPARγ ligands in a recent randomized clinical trial. Using cells and prostate cancer xenograft mouse models, we demonstrate in this study that a combination treatment using the PPARγ agonist pioglitazone and the histone deacetylase inhibitor valproic acid is more efficient at inhibiting prostate tumor growth than each individual therapy. We show that the combination treatment impairs the bone-invasive potential of prostate cancer cells in mice. In addition, we demonstrate that expression of E-cadherin, a protein involved in the control of cell migration and invasion, is highly up-regulated in the presence of valproic acid and pioglitazone. We show that E-cadherin expression responds only to the combination treatment and not to single PPARγ agonists, defining a new class of PPARγ target genes. These results open up new therapeutic perspectives in the treatment of prostate cancer.


Sign in / Sign up

Export Citation Format

Share Document